Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NILK 2401

Next Previous
Drug Profile

NILK 2401

Alternative Names: NI-2401; NILK-2401

Latest Information Update: 09 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NovImmune SA
  • Developer Light Chain Bioscience
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 08 Oct 2024 Phase-I clinical trials in Solid tumours in Spain (Parenteral)
  • 14 Apr 2023 Adverse events and pharmacodynamics data from preclinical studies in Solid tumours presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
  • 02 Sep 2022 Light Chain Bioscience announces intention to submit IND application of NI 2401 for Solid tumours in the Q4 of 2022 (LamKap Bio pipeline, September 2022)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top